Site master file SUP-ICU

EudraCT number 2015-000318-24

Table of contents

1) Protocol and trial synopsis
   a) Approved protocol
   b) Approved amendments
   c) Trial synopsis

2) CRF

3) Trial participants
   a) Delegation- and signature log
   b) Training log
   c) Curriculum Vitae for all personnell

4) Approvals and correspondence
   a) The Danish Health and Medicines Authority
   b) EudraCT
   c) The Committees on Health Research Ethics
   d) The Danish Data Protection Agency (Datatilsynet)
   e) National and local approvals
   f) Annual Safety Report

5) Collaboration agreement
   a) Collaboration agreement between Sponsor and site
   b) Approval from head of department
   c) Other relevant contracts

6) Financial affairs
   a) Case money
   b) Patient insurances (where relevant)

7) Information to paticipants
   a) Patient information
   b) Consent forms

8) Co-enrolment og substudies
   a) Co-enrolment form
   b) Quality criteria for substudies
   c) Substudy proposal form

9) Trial documents
   a) Trial instructions
      i) Eligibility
      ii) Screening and randomisation
      iii) Trial medication
      iv) eCRF
      v) SAR/SUSAR
   b) Pocket cards, documents for a notice board in the department
      i) Trial medication for notice board
      ii) Inclusion and exclusion criteria for notice board
      iii) Trial synopsis for notice board
      iv) Pocket cards
      v) Leaflet for clinicians/nurses
      vi) Sign for bed
      vii) Identification log
   c) Educational material (power point presentations)
      i) Background
      ii) Screening and randomisation
      iii) Trial medication
      iv) Data entry
      v) Withdrawal
      vi) SAR/SUSAR and undblinding
      vii) Information for nurses
      viii) Discharge/transfer/death

10) Trial medication
   a) Labels
   b) Summary of product characteristics

c) Drug disposal form
d) Receipt of trial medication
e) Instruction for temperature logger

11) Laboratory tests

12) Primary data source

13) Communication
a) Contact details – Steering Committee
b) Contact details – Denmark, Finland, Netherlands, Norway, UK, Italy, Switzerland
c) Note to file send to Sponsor
d) Note to file received from Sponsor
e) Other correspondances between Sponsor and site(s)
f) News letters
g) Investigator meeting

14) Serious adverse reactions and suspected unexpected serious adverse reactions
a) SAR/SUSAR form
b) Documentation for reporting of SAR/SUSAR

15) GCP unit
a) Contacts (monitors/GCP units)
b) Monitoring visits
c) Monitoring reports
d) Monitoring plan
e) Approval of trial initiation
f) Correspondance with the monitor (e.g. GCP-unit)

16) Trial completion